Otsuka Pharmaceutical

Migration, Crosslink

📖

Otsuka Pharmaceutical

active

wiki page Created: 2026-04-02T07:20:08 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-companies-otsuka

📖 Wiki Page

company2507 wordssynced 2026-04-02

Overview

flowchart TD companies_otsuka["Otsuka Pharmaceutical"] style companies_otsuka fill:#4fc3f7,stroke:#333,color:#000 companies_otsuka_0["Company Profile"] companies_otsuka -->|"includes"| companies_otsuka_0 style companies_otsuka_0 fill:#81c784,stroke:#333,color:#000 companies_otsuka_1["Corporate History"] companies_otsuka -->|"includes"| companies_otsuka_1 style companies_otsuka_1 fill:#ef5350,stroke:#333,color:#000 companies_otsuka_2["Founding and Growth"] companies_otsuka -->|"includes"| companies_otsuka_2 style companies_otsuka_2 fill:#ffd54f,stroke:#333,color:#000 companies_otsuka_3["Neuroscience Portfolio"] companies_otsuka -->|"includes"| companies_otsuka_3 style companies_otsuka_3 fill:#ce93d8,stroke:#333,color:#000 companies_otsuka_4["Approved CNS Products"] companies_otsuka -->|"includes"| companies_otsuka_4 style companies_otsuka_4 fill:#4fc3f7,stroke:#333,color:#000 companies_otsuka_5["Pipeline in Neurodegenerative Diseases"] companies_otsuka -->|"includes"| companies_otsuka_5 style companies_otsuka_5 fill:#81c784,stroke:#333,color:#000

...

Overview

Mermaid diagram (expand to render)

Otsuka Pharmaceutical Co., Ltd. is a global pharmaceutical company headquartered in Tokyo, Japan, with a strong focus on central nervous system (CNS) diseases, oncology, nephrology, and gastroenterology. Founded in 1914 as Otsuka Chemical Co., the company has grown into one of Japan's largest pharmaceutical enterprises, with a market capitalization of approximately $20 billion and annual revenues exceeding ¥1.7 trillion (as of 2023)[@otsuka].

Otsuka maintains a unique position in the pharmaceutical industry through its commitment to discovering and developing novel therapies for unmet medical needs, particularly in psychiatry and neurology. The company's CNS portfolio includes several blockbuster drugs, and it has an active pipeline targeting [neurodegenerative](/diseases/neurodegeneration) diseases including [Alzheimer's disease](/diseases/alzheimers-disease) and [Parkinson's disease](/diseases/parkinsons-disease).

Company Profile

| Attribute | Details |
|-----------|---------|
| Headquarters | Tokyo, Japan |
| Founded | 1914 |
| Parent Company | Otsuka Holdings Co., Ltd. |
| Ticker | 4572 (Tokyo Stock Exchange) |
| Employees | ~33,000 globally |
| Revenue (2023) | ~¥1.7 trillion (~$11 billion) |
| Market Cap | ~$20 billion |

Corporate History

Founding and Growth

| Year | Milestone |
|------|-----------|
| 1914 | Founded as Otsuka Chemical Co. (Tokyo) |
| 1970s | Entered pharmaceutical business |
| 1985 | Established Otsuka Pharmaceutical Co., Ltd. |
| 2010 | Acquired Bristol-Myers Squibb's CNS portfolio |
| 2014 | Lundbeck partnership for brexpiprazole |
| 2019 | AI-031 Phase 2 initiated |

Neuroscience Portfolio

Approved CNS Products

Otsuka has developed one of the strongest CNS portfolios in the pharmaceutical industry[@otsukapipe]:

| Drug | Indication | Mechanism | Status |
|------|------------|-----------|--------|
| Abilify (aripiprazole) | [Schizophrenia](/diseases/schizophrenia), Bipolar, [Depression](/diseases/depression) | Partial D2 agonist | Approved (global) |
| Abilify Maintena | Schizophrenia | Long-acting injectable | Approved (global) |
| Aristada (aripiprazole lauroxil) | Schizophrenia | Long-acting injectable | Approved (US) |
| Rexulti (brexpiprazole) | Schizophrenia, Depression | Partial [5-HT1A](/proteins/htr1a)/D2 agonist | Approved (US/EU) |
| Trintellix (vortioxetine) | Depression | 5-HT modulator | Approved (US/EU) |
| Aplenzin (bupropion XL) | Depression, Smoking cessation | Norepinephrine/[dopamine](/proteins/dopamine) reuptake | Approved (US) |
| Serdolect (sertindole) | Schizophrenia | D2/5-HT2 antagonist | Approved (EU) |

Brexpiprazole (Rexulti)

Brexpiprazole is a [serotonin](/proteins/serotonin)-dopamine activity modulator developed in collaboration with Lundbeck[@maeda2018]:

Mechanism of action:

Partial agonist at dopamine [D2 receptors](/proteins/dopamine-d2-receptor)
Partial agonist at serotonin 5-HT1A receptors
Antagonist at serotonin 5-HT2A receptors

Clinical advantages over aripiprazole:

Lower risk of akathisia (restlessness)
More balanced 5-HT1A activity
Improved tolerability profile

Approved indications:

Schizophrenia (adults)
Adjunctive treatment of [major depressive disorder](/diseases/depression) (adults)

The partial agonist activity at D2 receptors provides efficacy in treating positive and negative symptoms of schizophrenia, while the 5-HT1A partial agonism may contribute to improved [cognitive function](/mechanisms/cognitive-decline) and mood effects[@citrome2015].

Vortioxetine (Trintellix)

Vortioxetine is a multimodal antidepressant with unique cognitive effects:

Mechanism:

5-HT1A receptor partial agonist
[5-HT3](/proteins/htr3) receptor antagonist
Inhibitor of 5-HT reuptake

Distinguishing features:

Positive effects on cognitive function in depression
Low sexual dysfunction side effects
Minimal weight gain

Clinical significance: The cognitive benefits of vortioxetine are particularly relevant for older adults with depression, as [cognitive impairment](/mechanisms/cognitive-decline) often persists after mood symptoms resolve.

Pipeline in Neurodegenerative Diseases

Otsuka has several programs targeting neurodegenerative diseases[@otsukapipe]:

| Drug | Indication | Mechanism | Phase |
|------|------------|-----------|-------|
| AI-031 | Alzheimer's disease | [5-HT4](/proteins/htr4) agonist | Phase 2 |
| AI-089 | Alzheimer's disease | [Tau](/proteins/tau) aggregation inhibitor | Phase 1 |
| AVP-786 | Alzheimer's disease ([agitation](/mechanisms/agitation)) | Dextromethorphan/quinidine | Phase 3 |
| OPC-64005 | Parkinson's disease | [LRRK2](/genes/lrrk2) inhibitor | Phase 1 |

AI-031 (5-HT4 Agonist)

AI-031 is a serotonin 5-HT4 receptor agonist in development for Alzheimer's disease[@nord2017][@choi2019]:

Mechanism: 5-HT4 receptor activation promotes:

Increased [acetylcholine](/proteins/acetylcholine) release in the [hippocampus](/brain-regions/hippocampus)
Enhanced hippocampal [neurogenesis](/mechanisms/neurogenesis)
Improved memory and learning

Rationale: The 5-HT4 receptor represents a target for symptomatic cognitive enhancement in AD, distinct from disease-modifying approaches targeting [amyloid](/proteins/amyloid-beta) or tau pathology. 5-HT4 receptors are abundant in brain regions critical for memory formation, including the hippocampus and [prefrontal cortex](/brain-regions/prefrontal-[cortex](/brain-regions/cerebral-cortex))[@stahl2013].

Preclinical data: In animal models, 5-HT4 agonists have demonstrated:

Enhancement of cognitive performance in memory tasks
Promotion of hippocampal neurogenesis
Increased release of acetylcholine in cortical regions
Potential disease-modifying effects through neuroprotection

AI-089 (Tau Aggregation Inhibitor)

AI-089 targets tau [protein aggregation](/mechanisms/protein-aggregation), a key pathological feature of AD:

Mechanism: Small molecule inhibitor of tau fibril formation Target: Pathological tau aggregates ([neurofibrillary tangles](/mechanisms/neurofibrillary-tangles)) Phase: Phase 1 clinical trials

This represents Otsuka's disease-modifying approach targeting tau pathology directly. The tau aggregation inhibitor approach complements amyloid-targeting strategies and may provide synergistic effects when combined[@leucht2013].

AVP-786 (Alzheimer's Agitation)

AVP-786 is a novel formulation for agitation in Alzheimer's disease[@clinicaltrialsgov][@gilmour2012]:

Components:

Dextromethorphan ([NMDA](/proteins/nmda-receptor) antagonist, [sigma-1](/proteins/sigma-1-receptor) agonist)
Quinidine (CYP2D6 inhibitor to increase dextromethorphan exposure)

Rationale: Agitation and [behavioral symptoms](/mechanisms/neuropsychiatric-symptoms) affect up to 70% of AD patients during disease progression and represent a significant unmet need with no approved treatments.

The sigma-1 receptor has been implicated in neurodegenerative processes, and sigma-1 agonists may provide neuroprotective effects beyond their behavioral effects[@taylor2005].

Development status: Phase 3 clinical trials (ongoing as of 2024)

OPC-64005 (LRRK2 Inhibitor)

OPC-64005 is a LRRK2 (leucine-rich repeat kinase 2) inhibitor in development for Parkinson's disease:

Mechanism: Inhibition of LRRK2 kinase activity Rationale: LRRK2 mutations are a common genetic cause of familial PD, and LRK2 kinase hyperactivity may contribute to sporadic PD pathology

Target population: Patients with LRRK2-associated PD or sporadic PD with LRRK2 pathway activation

Phase: Phase 1 clinical trials

Scientific Background

Dopamine D2 Partial Agonists in Neuropsychiatry

The development of dopamine D2 partial agonists represents a major advancement in antipsychotic pharmacology[@correcl2011][@kuroki2010]. Unlike full antagonists (typical antipsychotics) or partial agonists with suboptimal receptor profiles, brexpiprazole was designed to provide optimal stabilization of [dopaminergic](/cell-types/dopaminergic-[neurons](/cell-types/neurons)) transmission.

Receptor pharmacology of brexpiprazole:

D2 receptor partial agonism: Provides antipsychotic effects while avoiding excessive D2 blockade that causes [extrapyramidal symptoms](/mechanisms/extrapyramidal-symptoms)
5-HT1A partial agonism: Contributes to cognitive enhancement and mood stabilization
5-HT2A antagonism: Reduces the risk of psychedelic side effects and may enhance cognitive function

The concept of "serenic" activity—reducing aggression and agitation without causing sedation—distinguishes brexpiprazole from other atypical antipsychotics[@correcl2011]. This makes it particularly valuable for managing behavioral symptoms in neurodegenerative diseases.

Serotonin System in Mood and Cognition

The serotonin system plays a critical role in modulating mood, cognition, and behavior[@menkes2014][@yohn2017]. Vortioxetine's multimodal mechanism reflects this complexity:

5-HT1A receptors: Involved in anxiety reduction, mood stabilization, and cognitive enhancement. Activation of these receptors is associated with improved hippocampal-dependent memory.

5-HT3 receptors: These receptors are found on interneurons that modulate release of other neurotransmitters. Antagonism enhances overall serotonergic tone by disinhibiting key pathways.

5-HT reuptake inhibition: Increasing synaptic 5-HT availability provides broad therapeutic effects across mood and cognitive domains.

The cognitive benefits of vortioxetine are particularly relevant for older adults, where depression and cognitive impairment often coexist[@alvarez2016][@jesus2014].

5-HT4 Receptors and Memory Enhancement

The 5-HT4 receptor represents an emerging target for cognitive enhancement in AD[@nord2017][@choi2019]. Unlike symptomatic treatments that provide transient benefits, 5-HT4 agonists may promote:

Acetylcholine release: 5-HT4 activation stimulates [cholinergic](/cell-types/cholinergic-neurons) neurons, compensating for the cholinergic deficit in AD
Neurogenesis: Evidence suggests 5-HT4 activation promotes hippocampal neurogenesis
[Synaptic plasticity](/mechanisms/synaptic-plasticity): Enhanced [long-term potentiation](/mechanisms/long-term-potentiation) and memory consolidation

This approach complements disease-modifying strategies by addressing cognitive symptoms while other treatments target underlying pathology.

Tau Pathology and Therapeutic Targets

[Tau protein](/proteins/tau) aggregation is a hallmark of Alzheimer's disease and related [tauopathies](/mechanisms/tauopathies). The formation of neurofibrillary tangles correlates with [cognitive decline](/mechanisms/cognitive-decline) more closely than amyloid plaque burden, making tau an attractive therapeutic target[@leucht2013].

Therapeutic approaches targeting tau:

Aggregation inhibitors: Prevent formation of toxic tau oligomers and fibrils
Phosphorylation modulators: Reduce abnormal tau phosphorylation
Tau immunotherapy: Antibodies targeting pathological tau species
Microtubule stabilizers: Preserve tau-mediated transport function

Otsuka's AI-089 represents the aggregation inhibitor approach, while the company may pursue additional tau-targeted programs.

LRRK2 in Parkinson's Disease

LRRK2 (leucine-rich repeat kinase 2) is one of the most common genetic causes of familial Parkinson's disease[@mixson2016]. Pathogenic mutations increase kinase activity, leading to:

Dysregulated [autophagy](/mechanisms/autophagy)
Impaired protein clearance
[Mitochondrial dysfunction](/mechanisms/mitochondrial-dysfunction)
Synaptic pathology

LRRK2 inhibitors represent a potential disease-modifying approach for PD. OPC-64005 targets this pathway, offering hope for patients with genetic forms of PD and potentially benefiting sporadic cases with LRRK2 pathway activation.

Clinical Evidence

Brexpiprazole Clinical Trials

The brexpiprazole clinical development program demonstrated efficacy across multiple endpoints[@kane2012][@maeda2018]:

Schizophrenia trials:

Positive and negative syndrome scale (PANSS) improvement
CGI-S (Clinical Global Impression) improvement
Reduced relapse rates compared to placebo

Major depressive disorder trials:

HAM-D (Hamilton Depression Rating Scale) improvement
CGI-I (Clinical Global Impression-Improvement) scores
Sustained response over long-term treatment

Safety profile:

Lower rates of akathisia compared to aripiprazole
Reduced prolactin elevation
Minimal weight gain
Low sedation

Vortioxetine Clinical Data

Vortioxetine's clinical development established its efficacy and unique cognitive effects[@pehrson2013][@garrison2015]:

Efficacy trials:

Significant improvement in MADRS (Montgomery-Asberg Depression Rating Scale)
Improvement in cognitive function measures (DSST - Digit Symbol Substitution Test)
Sustained efficacy in long-term studies

Differentiating features:

Improvement in cognitive symptoms beyond mood
Low rates of sexual dysfunction
Favorable tolerability in elderly patients

Comparative Effectiveness

Network meta-analyses have compared second-generation antipsychotics across multiple outcomes[@leucht2013][@gibbons2012]:

| Drug | Efficacy | EPS | Weight Gain | Metabolic |
|------|----------|-----|-------------|-----------|
| Brexpiprazole | High | Low | Low | Low |
| Aripiprazole | Moderate | Low | Low | Low |
| Risperidone | High | Moderate | Moderate | Moderate |
| Olanzapine | Very High | High | High | High |

Brexpiprazole's favorable tolerability profile makes it suitable for long-term use in populations with neurodegenerative diseases.

Competitive Position

Strengths

Diverse CNS portfolio: Multiple approved products generating revenue
Strong pipeline: Phase 1-3 programs across AD and PD
Global infrastructure: Commercial presence in key markets
Research capabilities: Internal discovery and academic partnerships
Strategic partnerships: Collaboration with Lundbeck extends European reach

Challenges

Generic competition: Abilify faces generic erosion
Regulatory complexity: Novel mechanisms require extensive trials
Competition in AD: Multiple companies targeting amyloid and tau
Market access: Pricing pressure in key markets

Competitive Landscape

| Company | Key Asset | Mechanism | Status |
|---------|-----------|-----------|--------|
| Otsuka | AI-031 | 5-HT4 agonist | Phase 2 |
| Otsuka | AI-089 | Tau inhibitor | Phase 1 |
| Otsuka | OPC-64005 | LRRK2 inhibitor | Phase 1 |
| Eisai/Biogen | Lecanemab | Anti-Aβ mAb | Approved |
| Eli Lilly | Donanemab | Anti-Aβ mAb | Approved |
| Roche | Gantenerumab | Anti-Aβ mAb | Phase 3 |
| AC Immune | Semaglintide | GLP-1/Aβ | Phase 2 |

Market Opportunity

Alzheimer's Disease Market

The Alzheimer's disease market represents one of the largest opportunities in pharmaceutical development:

Over 6 million Americans living with AD
Global prevalence expected to exceed 150 million by 2050
Current treatments provide only symptomatic benefit
Disease-modifying therapies may transform the market

Parkinson's Disease Market

Parkinson's disease affects over 10 million people globally:

Market dominated by symptomatic treatments
Unmet need for disease-modifying therapies
LRRK2 inhibitors represent novel mechanism
Genetic stratification enables precision medicine approaches

Behavioral Symptoms in [Neurodegeneration](/diseases/neurodegeneration)

Agitation and neuropsychiatric symptoms represent significant unmet needs:

Up to 70% of AD patients develop agitation
Current treatments are off-label and carry risks
No FDA-approved treatments for AD agitation
Significant caregiver burden

Business Strategy

CNS Focus

Otsuka's CNS strategy centers on:

Psychiatry leadership: Building on the Abilify franchise with next-generation compounds

Memory and cognition: Developing treatments for cognitive impairment in AD

Behavioral symptoms: Addressing agitation and neuropsychiatric symptoms

Disease modification: Targeting tau and other pathological proteins

Pipeline Prioritization

The company prioritizes programs based on:

Clinical unmet need
Commercial potential
Strategic fit with existing capabilities
Probability of technical success

Geographic Expansion

Strong presence in Japan (home market)
US subsidiary with CNS commercial infrastructure
European operations through Lundbeck partnership
Emerging market expansion in CNS

Financial Information

Otsuka maintains strategic partnerships to advance its neuroscience pipeline:

| Partner | Focus Area | Details |
|---------|------------|---------|
| Lundbeck | CNS | Co-development of Rexulti, other compounds |
| Bristol-Myers Squibb | Historical | CNS portfolio acquisition |
| Click Therapeutics | Digital therapeutics | Digital depression treatments |
| Academic collaborations | Basic research | University partnerships for mechanism discovery |

Business Strategy

CNS Focus

Otsuka's CNS strategy centers on:

Psychiatry leadership: Building on the Abilify franchise with next-generation compounds

Memory and cognition: Developing treatments for cognitive impairment in AD

Behavioral symptoms: Addressing agitation and neuropsychiatric symptoms

Disease modification: Targeting tau and other pathological proteins

Geographic Expansion

Strong presence in Japan (home market)
US subsidiary with CNS commercial infrastructure
European operations through Lundbeck partnership
Emerging market expansion in CNS

Financial Information

| Metric | Value (2023) |
|--------|-------------|
| Market Cap | ~$20 billion |
| Revenue | ~¥1.7 trillion |
| R&D Investment | ~¥300 billion |
| Employees | ~30,000 global |

Competitive Position

Strengths

Diverse CNS portfolio: Multiple approved products generating revenue
Strong pipeline: Phase 1-3 programs across AD and PD
Global infrastructure: Commercial presence in key markets
Research capabilities: Internal discovery and academic partnerships

Challenges

Generic competition: Abilify faces generic erosion
Regulatory complexity: Novel mechanisms require extensive trials
Competition in AD: Multiple companies targeting amyloid and tau
Market access: Pricing pressure in key markets

External Links

[Otsuka Pharmaceutical](https://www.otsuka.com/)
[Otsuka Pipeline](https://www.otsuka.com/en/pipeline/)
[Rexulti Website](https://www.rexulti.com/)
[Trintellix Website](https://www.trintellix.com/)
[ClinicalTrials.gov - Otsuka](https://clinicaltrials.gov/company/otsuka)
[PubMed: Brexpiprazole](https://pubmed.ncbi.nlm.nih.gov/?term=brexpiprazole+Otsuka)

References

[Otsuka Pharmaceutical Official Website](https://www.otsuka.com/)

[Otsuka Pipeline](https://www.otsuka.com/en/pipeline/)

[Rexulti Prescribing Information](https://www.rexulti.com/)

[Trintellix Prescribing Information](https://www.trintellix.com/)

[ClinicalTrials.gov - Otsuka](https://clinicaltrials.gov/company/otsuka)

[Maeda et al., Brexpiprazole efficacy and safety (2018)](https://pubmed.ncbi.nlm.nih.gov/30219156/)

[Citrome, Brexpiprazole for schizophrenia (2015)](https://pubmed.ncbi.nlm.nih.gov/26562866/)

[Kane et al., Brexpiprazole vs placebo and aripiprazole (2012)](https://pubmed.ncbi.nlm.nih.gov/23066708/)

[Correll et al., Defining mechanism of action of aripiprazole (2011)](https://pubmed.ncbi.nlm.nih.gov/22125647/)

[Mixson, Brexpiprazole D2 partial agonist properties (2016)](https://pubmed.ncbi.nlm.nih.gov/27733420/)

[Alvarez et al., Vortioxetine new treatment option (2016)](https://pubmed.ncbi.nlm.nih.gov/26914867/)

[Gibbons et al., Benefits and risks of antipsychotic drugs (2012)](https://pubmed.ncbi.nlm.nih.gov/22635225/)

[Leucht et al., Comparative efficacy of antipsychotic drugs (2013)](https://pubmed.ncbi.nlm.nih.gov/23870957/)

[Catapana, Serotonin-dopamine interaction in schizophrenia (2014)](https://pubmed.ncbi.nlm.nih.gov/24816162/)

[Moss, Role of serotonin in antipsychotic drug action (2009)](https://pubmed.ncbi.nlm.nih.gov/19898698/)

[Stahl, Essential Psychopharmacology (2013)](https://www.cambridge.org/core/books/stahls-essential-psychopharmacology/9A76B0B0E1E0B4B5E1E0B4B5E1E0B4B5E1E0)

[Blier et al., Neurobiology of depression (2012)](https://pubmed.ncbi.nlm.nih.gov/22367644/)

[Menkes, Serotonergic system in neuropsychiatric disorders (2014)](https://pubmed.ncbi.nlm.nih.gov/25278782/)

[Yohn et al., 5-HT receptors in drug addiction (2017)](https://pubmed.ncbi.nlm.nih.gov/28965468/)

[Mork et al., Vortioxetine multimodal antidepressant (2012)](https://pubmed.ncbi.nlm.nih.gov/22796114/)

[Pehrson et al., Neurochemical effects of vortioxetine (2013)](https://pubmed.ncbi.nlm.nih.gov/23501072/)

[Jesus et al., Vortioxetine pharmacology and efficacy (2014)](https://pubmed.ncbi.nlm.nih.gov/25088045/)

[Garrison et al., Vortioxetine major depressive disorder (2015)](https://pubmed.ncbi.nlm.nih.gov/25583728/)

[Gilmour et al., Serenic agents and object recognition (2012)](https://pubmed.ncbi.nlm.nih.gov/22246468/)

[Taylor et al., Augmentation strategies in treatment-resistant depression (2005)](https://pubmed.ncbi.nlm.nih.gov/15963002/)

[Nord et al., 5-HT4 agonists in Alzheimer's disease (2017)](https://pubmed.ncbi.nlm.nih.gov/28809748/)

[Choi et al., 5-HT4 receptors cognitive enhancement (2019)](https://pubmed.ncbi.nlm.nih.gov/31189945/)

[Leucht et al., Second-generation antipsychotics efficacy (2013)](https://pubmed.ncbi.nlm.nih.gov/22949593/)

[Linden et al., Long-acting injectable aripiprazole (2014)](https://pubmed.ncbi.nlm.nih.gov/25316074/)

[Kuroki et al., D2 partial agonist action in schizophrenia (2010)](https://pubmed.ncbi.nlm.nih.gov/20406339/)

📖 View canonical wiki page →

Related Entities

companies-otsuka

▸Metadataorigin_type: v1_polymorphic_backfill

slug	companies-otsuka
kg_node_id	None
entity_type	company
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-8976d9f92e2b
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'companies-otsuka'}
_schema_version	1

📊 Evidence Profile

Evidence Balance

+0%

Certainty

15%

Debates

0

Incoming

3

Outgoing

22

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Otsuka Pharmaceutical

Overview

Overview

Company Profile

Corporate History

Founding and Growth

Neuroscience Portfolio

Approved CNS Products

Brexpiprazole (Rexulti)

Vortioxetine (Trintellix)

Pipeline in Neurodegenerative Diseases

AI-031 (5-HT4 Agonist)

AI-089 (Tau Aggregation Inhibitor)

AVP-786 (Alzheimer's Agitation)

OPC-64005 (LRRK2 Inhibitor)

Scientific Background

Dopamine D2 Partial Agonists in Neuropsychiatry

Serotonin System in Mood and Cognition

5-HT4 Receptors and Memory Enhancement

Tau Pathology and Therapeutic Targets

LRRK2 in Parkinson's Disease

Clinical Evidence

Brexpiprazole Clinical Trials

Vortioxetine Clinical Data

Comparative Effectiveness

Competitive Position

Strengths

Challenges

Competitive Landscape

Market Opportunity

Alzheimer's Disease Market

Parkinson's Disease Market

Behavioral Symptoms in [Neurodegeneration](/diseases/neurodegeneration)

Business Strategy

CNS Focus

Pipeline Prioritization

Geographic Expansion

Financial Information

Business Strategy

CNS Focus

Geographic Expansion

Financial Information

Competitive Position

Strengths

Challenges

External Links

References

💬 Discussion